View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	May 31, 2014	Jul. 11, 2014
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	May 31, 2014
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Current Fiscal Year End Date	--08-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,955,991

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2014	Aug. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 2,474,839	$ 2,272,228
Short term deposits	12,005,172	5,246,627
Marketable securities	1,063,409	956,376
Restricted cash	61,000	16,000
Prepaid expenses and other current assets	97,525	90,103
Related parties	523	4,530
Grants receivable from the chief scientist	267,131	58,412
T o t a l current assets	15,969,599	8,644,276
LONG TERM DEPOSITS AND INVESTMENT	6,508,269	4,593
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	6,688	5,545
PROPERTY AND EQUIPMENT, NET	13,547	5,768
T o t a l assets	22,498,103	8,660,182
CURRENT LIABILITIES:
Accounts payable and accrued expenses	447,792	450,941
Account payable with former shareholder	47,252	47,252
T o t a l current liabilities	495,044	498,193
LONG TERM LIABILITIES:
Employee rights upon retirement	8,732	8,004
Provision for uncertain tax position	23,210	23,210
Total long term liabilities	31,942	31,214
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $ 0.012 par value (16,666,667 authorized shares; 9,955,991 and 7,937,872 shares issued and outstanding as of May 31, 2014 and August 31, 2013, respectively)	119,456	95,238
Additional paid-in capital	47,574,340	29,855,723
Accumulated other comprehensive income	467,974	303,403
Accumulated deficit	(26,190,653)	(22,123,589)
T o t a l stockholders' equity	21,971,117	8,130,775
T o t a l liabilities and stockholders' equity	$ 22,498,103	$ 8,660,182

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	May 31, 2014	Aug. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value per share	$ 0.012	$ 0.012
Common stock, shares authorized	16,666,667	16,666,667
Common stock, shares issued	9,955,991	7,937,872
Common stock, shares outstanding	9,955,991	7,937,872

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2014	May 31, 2013	May 31, 2014	May 31, 2013
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, net	$ 1,089,298	$ 835,636	$ 2,513,142	$ 1,977,258
GENERAL AND ADMINISTRATIVE EXPENSES	813,923	499,034	1,743,902	1,349,081
OPERATING LOSS	1,903,221	1,334,670	4,257,044	3,326,339
FINANCIAL INCOME	(79,486)	(84,594)	(199,566)	(223,638)
FINANCIAL EXPENSES	4,167	6,265	9,586	338,267
NET LOSS FOR THE PERIOD	1,827,902	1,256,341	4,067,064	3,440,968
SUBSEQUENT (INCREASE) DECREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	19,664	38,967	(34,156)	(84,010)
RECLASSIFICATION ADJUSTMENT TO FINANCIAL INCOME OF GAINS ON AVAILABLE-FOR-SALE SECURITIES	35,626	18,491	80,017	69,178
UNREALIZED (GAIN) LOSS ON AVAILABLE FOR SALE SECURITIES	323,721	55,126	(210,432)	(117,092)
TOTAL OTHER COMPREHENSIVE (INCOME) LOSS	379,011	112,584	(164,571)	(131,924)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 2,206,913	$ 1,368,925	$ 3,902,493	$ 3,309,044
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.18	$ 0.17	$ 0.45	$ 0.49
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	9,888,126	7,223,377	8,988,446	7,087,831

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended May 31, 2014 - USD ($)	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income [Member]	Accumulated deficit [Member]
BALANCE at Aug. 31, 2013	$ 8,130,775	$ 95,238	$ 29,855,723	$ 303,403	$ (22,123,589)
BALANCE, shares at Aug. 31, 2013	7,937,872	7,937,872
SHARES ISSUED FOR CASH, NET	$ 14,887,085	$ 18,960	14,868,125
SHARES ISSUED FOR CASH, NET, shares	1,580,000	1,580,000
SHARES ISSUED FOR SERVICES	$ 64,400	$ 120	64,280
SHARES ISSUED FOR SERVICES, shares		10,000
SHARES ISSUED		$ 27	(27)
SHARES ISSUED, shares	2,252	2,252
EXERCISE OF WARRANTS AND OPTIONS	$ 1,751,188	$ 5,111	1,746,077
EXERCISE OF WARRANTS AND OPTIONS, shares		425,867
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	1,003,735		1,003,735
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	36,427		36,427
NET LOSS	(4,067,064)				(4,067,064)
OTHER COMPREHENSIVE INCOME	164,571			164,571
BALANCE at May. 31, 2014	$ 21,971,117	$ 119,456	$ 47,574,340	$ 467,974	$ (26,190,653)
BALANCE, shares at May. 31, 2014	9,955,991	9,955,991

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	May 31, 2014	May 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,067,064)	$ (3,440,968)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	4,079	3,697
Exchange differences and interest on deposits	(13,140)	10,880
Stock based compensation	1,040,162	627,511
Shares issued for services rendered	64,400	93,713
Gain on sale of investment	(80,017)	(69,178)
Exchange of warrants		296,982
Changes in fair value of warrant liabilities		(44,699)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(212,134)	(400,523)
Accounts payable and accrued expenses	(3,149)	(198,401)
Liability of employee rights upon retirement	728	5,821
Total net cash used in operating activities	(3,266,135)	(3,115,165)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(11,858)	(4,659)
Acquisition of short-term investments and short-term deposits	(41,745,000)	(2,317,198)
Acquisition of long term deposits	(6,500,000)
Funds related to employee rights upon retirement	(884)	(3,023)
Proceeds from sale of investment and marketable securities	137,555	226,671
Proceeds from sale of short term deposits	34,940,776	454,381
Total net cash used in investing activities	(13,179,411)	(1,643,828)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of common stock and warrants - net of issuance expenses	14,887,085	1,450,936
Proceeds from exercise of warrants and options	1,751,188
Net cash derived from financing activities	16,638,273	1,450,936
EFFECT OF EXCHANGE RATE CHANGES ON CASH	9,884	(17,786)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	202,611	(3,325,843)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	2,272,228	4,430,740
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2,474,839	1,104,897
Non cash investing and financing activities:
Exchange of warrants		917,809
Shares and warrants issued for marketable securities		$ 628,630

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

May 31, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011. See also note 2a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary").

Development and liquidity risks

The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.

Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Newly issued and recently adopted Accounting Pronouncements

In June 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation ("ASU 2014-10"). This update removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from accounting principles generally accepted in the United States of America ("U.S. GAAP"). In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued. The Company has elected to early adopt the provisions of ASU 2014-10 in the third quarter of fiscal year 2014.

In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The Company adopted ASU 2013-02 in the first quarter of fiscal year 2014. The adoption of ASU 2013-02 did not have any material effect on the consolidated financial statement presentation.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with U.S. GAAP and on the same basis as the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended August 31, 2013 (the "2013 Form 10-K"). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2013 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year's results.

COMMITMENTS

9 Months Ended

May 31, 2014

COMMITMENTS [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Agreement") to retain consulting and clinical trial services. According to the Agreement, Hadasit will be entitled to a consideration of $200,000 to be paid by the Company in accordance with the actual progress of the studies, $95,000 of which were paid and recognized through May 31, 2014. See also note 1a(1).

On July 5, 2010, the Subsidiary of the Company entered into a Manufacturing Supply Agreement ("MSA") with Sanofi-Aventis Deutschland GMBH ("Sanofi"). According to the MSA, Sanofi will supply the Subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.

On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera Bio Ltd ("Entera") on March 31, 2011 and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of May 31, 2014 was $100,441, using the following assumptions: dividend yield of 0% and expected term of 6.72 years; expected volatility of 82.19%; and risk-free interest rate of 2.24%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On March 18, 2012, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement was for a period of 57 months commencing January 1, 2012.

On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel, which replaced the lease agreement from 2012. The new lease agreement is for a period of 36 months commencing November 4, 2013. The annual lease payment will be NIS 89,052 from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index ("CPI") (as of May 31, 2014, the future annual lease payments under the new agreement will be $25,626, based on the exchange rate as of May 31, 2014).

The lease expenses for the nine and three month periods ended May 31, 2014 were approximately $16,081 and $6,478, respectively.

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On April 15, 2013, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company's common stock issued in three equal installments, on each of May 1, 2013, August 1, 2013 and November 15, 2013. On July 11 and November 4, 2013 the Company issued to such advisor 5,000 and 10,000 shares, respectively. The fair value of the shares at these dates was $34,900 and $64,400, respectively. See also note 5a.

On May 13, 2014, the Company entered into an additional consulting agreement with the same third party advisor for a period of an additional twelve months, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company's common stock that will be issued in four equal installments, on each of August 1, 2014, November 1, 2014, February 1, 2015 and May 1, 2015.

On April 29, 2013, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a Clinical Research Organization ("CRO"), for its Phase 2a clinical trial for an oral insulin capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $332,702 that will be paid during the term of the engagement and based on achievement of certain milestones, $282,807 of which were paid and recognized through May 31, 2014.

On February 6, 2014, the Subsidiary entered into an additional agreement with the same CRO, to retain it as a CRO, for its Phase 2a clinical trial for an oral insulin capsule for type 1 diabetes patients, which is expected to be completed in approximately nine months. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $280,008 that will be paid during the term of the engagement and based on achievement of certain milestones, $140,000 of which were paid and recognized through May 31, 2014.

On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102,280, of which $68,187 were paid and recognized through May 31, 2014.

On March 3, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of one of its oral capsule ingredients in a different technology in the amount of $310,500, and bonus payments of up to $600,000 that will be paid upon achieving certain milestones, as described in the agreement. The Subsidiary paid and recognized $15,000 of said amount through May 31, 2014.

On May 15, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $214,000, of which $103,370 were paid and recognized through May 31, 2014.

On May 26, 2014, the Subsidiary entered into a supply agreement with a vendor, according to which, the vendor will manufacture insulin capsules for total consideration of $214,100, none of which was paid or recognized through May 31, 2014.

Grants from Bio-Jerusalem

The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65,053. As of May 31, 2014, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

During the nine and three month periods ended May 31, 2014, the Company received no grants from the Bio-Jerusalem fund.

Grants from the Office of the Chief Scientist of the Ministry of Economy (formerly the Ministry of Industry, Trade and Labor) of Israel ("OCS").

Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

On May 31, 2014, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through May 31, 2014 is $1,783,994.

For the nine and three month periods ended May 31, 2014, the research and development expenses are presented net of OCS and Bio-Jerusalem fund grants, in the total amount of $333,522 and $194,081, respectively.

FAIR VALUE

9 Months Ended

May 31, 2014

FAIR VALUE [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of May 31, 2014 and August 31, 2013, the assets or liabilities measured at fair value were comprised of available for sale securities (level 1). See also note 4.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of May 31, 2014, the carrying amount of cash and cash equivalents, short term deposits, accounts receivable, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.

The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

In order to secure the fulfillment of the Company's obligations under credit cards, the Company has placed a restricted deposit with the bank in an amount of $61,000.

The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

MARKETABLE SECURITIES

9 Months Ended

May 31, 2014

MARKETABLE SECURITIES [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

As of May 31, 2014, marketable securities consisted wholly of equity securities of D.N.A Biomedical Solutions Ltd ("D.N.A").

During the nine months ended May 31, 2014, the Subsidiary sold in aggregate 2,625,989 of the D.N.A shares for a total of $137,555.

As of May 31, 2014, the Group owns approximately 9.8% of D.N.A's outstanding ordinary shares.

The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into financial income (amounting to $80,017 during the nine month period ended May 31, 2014), were determined by specific identification.

The D.N.A. shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

As of May 31, 2014 and August 31, 2013, the available for sale securities are classified as level 1 as described in the table below:

	Level 1
Marketable securities:
May 31, 2014	$	1,063,409
August 31, 2013	$	956,376

Available-for-sale securities are reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

STOCK HOLDERS' EQUITY

9 Months Ended

May 31, 2014

STOCK HOLDERS' EQUITY [Abstract]

STOCK HOLDERS' EQUITY

NOTE 5 - STOCK HOLDERS' EQUITY:

As described in note 2e, onNovember 4, 2013, the Company issued 10,000 shares of its common stock to an advisor as remuneration for services rendered. The total fair value of the shares at the date of grant was $64,400.

On December 24, 2013, the Company entered into a Placement Agency Agreement with Aegis Capital Corp. (the "Placement Agent"), pursuant to which the Placement Agent agreed to use its reasonable best efforts to arrange for the sale of up to 1,580,000 shares of the Company's common stock. In connection therewith, on December 24, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 1,580,000 shares of common stock, at a price of $10.00 per share, to two institutional investors in a registered direct offering (the "Offering"). The Company received all funds and issued all shares of common stock in connection with the Offering as of December 30, 2013. The net proceeds to the Company from the Offering were approximately $14,887,085, after deducting Placement Agent's commissions of $815,500 and other offering expenses of the Company.

During January and April 2014, 398,965 warrants were exercised for cash and resulted in the issuance of 398,965 shares of common stock. The cash consideration received for the exercise of the warrants was $1,571,638.

During January through April 2014, 26,902 options were exercised as part of the Company's stock based compensation plan for cash and resulted in the issuance of 26,902 shares of common stock. The cash consideration received for exercise of the options was $179,550.

In May 2014, the Company issued 2,252 shares of its common stock as payment of liquidated damages related to certain registration rights contained in a 2012 securities purchase agreement.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

STOCK BASED COMPENSATION

9 Months Ended

May 31, 2014

STOCK BASED COMPENSATION [Abstract]

STOCK BASED COMPENSATION

NOTE 6 - STOCK BASED COMPENSATION:

On April 9, 2014, options to purchase an aggregate of 94,268 shares of the Company were granted to Nadav Kidron, the Company's President, Chief Executive Officer and a director, and Miriam Kidron, the Company's Chief Medical and Technology Officer and a director, both related parties, at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vested with respect to 31,420 shares of common stock on April 30, 2014, and the remaining shares of common stock will vest in eight equal monthly installments of 7,586 each. These options expire on April 9, 2024. The fair value of these options on the date of grant was $781,391, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.21 years.

On April 9, 2014, options to purchase an aggregate of 52,376 shares of the Company were granted to four Board of Directors members at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vest in two equal installments, on July 1, 2014 and January 1, 2015, and expire on April 9, 2024. The fair value of these options on the date of grant was $217,711, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.25 years.

On April 9, 2014, options to purchase 2,556 shares of the Company were granted to an employee of the Subsidiary, at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vest in four equal quarterly installments, commencing May 1, 2014, and expire on April 9, 2024. The fair value of these options on the date of grant was $21,220, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.23 years.

SIGNIFICANT ACCOUNTING POLICIES (Policy)

9 Months Ended

May 31, 2014

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

General:

Incorporation and operations

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

Development and liquidity risks

Newly issued and recently adopted Accounting Pronouncements

b.	Newly issued and recently adopted Accounting Pronouncements

Condensed Consolidated Financial Statements Preparation

MARKETABLE SECURITIES (Tables)

9 Months Ended

May 31, 2014

MARKETABLE SECURITIES [Abstract]

Schedule of Marketable Securities

As of May 31, 2014 and August 31, 2013, the available for sale securities are classified as level 1 as described in the table below:

	Level 1
Marketable securities:
May 31, 2014	$	1,063,409
August 31, 2013	$	956,376

COMMITMENTS (Service Agreements) (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended		146 Months Ended
COMMITMENTS (Service Agreements) (Details) - USD ($)	May 31, 2014	May 31, 2014	May 31, 2013	Aug. 31, 2013	Aug. 31, 2011	May 31, 2014
Long-term Purchase Commitment [Line Items]
Shares issued for services		10,000
Shares issued for services rendered		$ 64,400	$ 93,713
Hadasit [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services						$ 200,000
Consulting services						95,000
Consultant [Member]
Long-term Purchase Commitment [Line Items]
Agreement term					5 years
Commitments for consulting service, monthly fixed fee	$ 8,000	$ 8,000				$ 8,000
Royalty percentage	8.00%	8.00%				8.00%
Options granted					20,834
Options granted, exercise price					$ 6.00
Vesting period					5 years
Capitalized cost		$ 100,441			$ 62,185
Dividend yield		0.00%			0.00%
Expected volatility		82.19%			78.65%
Risk-free interest rate		2.24%			3.62%
Expected term		6 years 8 months 19 days			10 years
Advisor [Member]
Long-term Purchase Commitment [Line Items]
Shares authorized for issuance for services		15,000		15,000
Shares issued for services		10,000		5,000
Shares issued for services rendered		$ 64,400		$ 34,900
First Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services				102,280
Consulting services						$ 68,187
Clinical Research Organization Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services		280,008		$ 332,702
Consulting services		$ 140,000				282,807
Second Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services	$ 310,500
Commitments for bonus payments upon achieving certain milestones	600,000
Consulting services						15,000
Third Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services	214,000
Consulting services						103,370
Fourth Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services	$ 214,100
Consulting services

COMMITMENTS (Leases) (Details)	3 Months Ended	9 Months Ended	12 Months Ended
COMMITMENTS (Leases) (Details)	May 31, 2014 USD ($)	May 31, 2014 USD ($)	Aug. 31, 2012	May 31, 2014 ILS (₪)
COMMITMENTS [Abstract]
Operating lease term		36 months	57 months
Annual lease payments:
2014	$ 25,626	$ 25,626		₪ 89,052
2015	25,626	25,626		89,052
2016	25,626	25,626		₪ 89,052
Lease expense	$ 6,478	$ 16,081

COMMITMENTS (Research Grants) (Details)	3 Months Ended	9 Months Ended	146 Months Ended
COMMITMENTS (Research Grants) (Details)	May 31, 2014 USD ($)	May 31, 2014 USD ($)	May 31, 2014 USD ($)
Bio-Jerusalem [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	4.00%	4.00%	4.00%
Royalty percentage, maximum percentage of grants received	100.00%	100.00%	100.00%
Royalty liability	$ 0	$ 0	$ 0
Grants receivable	65,053	65,053	$ 65,053
Grants received	$ 0	$ 0
Chief Scientist Office [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage, maximum percentage of grants received	100.00%	100.00%	100.00%
Grants received	$ 194,081	$ 333,522	$ 1,783,994
Chief Scientist Office [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	3.00%	3.00%	3.00%
Chief Scientist Office [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage	3.50%	3.50%	3.50%

FAIR VALUE (Details)	May 31, 2014 USD ($)
FAIR VALUE [Abstract]
Restricted deposit	$ 61,000

MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended		9 Months Ended
MARKETABLE SECURITIES (Details) - USD ($)	May 31, 2014	May 31, 2013	May 31, 2014	May 31, 2013	Aug. 31, 2013
MARKETABLE SECURITIES [Abstract]
Number of shares sold			2,625,989
Proceeds from sale of marketable securities			$ 137,555
Ownership percentage	9.80%		9.80%
Amount reclassified to earnings	$ 35,626	$ 18,491	$ 80,017	$ 69,178
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 1,063,409		$ 1,063,409		$ 956,376

STOCK HOLDERS' EQUITY (Details) - USD ($)	9 Months Ended
STOCK HOLDERS' EQUITY (Details) - USD ($)	May 31, 2014	May 31, 2013
STOCK HOLDERS' EQUITY [Abstract]
Shares issued for services	10,000
Value of shares issued for services	$ 64,400	$ 93,713
Shares issued for cash	1,580,000
Shares issued for cash, price per share	$ 10
Proceeds from issuance of common stock	$ 14,887,085
Stock issuance costs including commisions	$ 815,500
Number of warrants exercised	398,965
Proceeds from exercise of warrants	$ 1,571,638
Shares issued for stock options exercised	26,902
Proceeds from exercise of stock options	$ 179,550
Shares issued for warrants exercised	398,965
Number of shares issued for liquidation damage fee	2,252

STOCK BASED COMPENSATION (Details)	1 Months Ended
STOCK BASED COMPENSATION (Details)	Apr. 30, 2014 $ / shares shares
Nadav Kidron and Miriam Kidron [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted \| shares	94,268
Options granted, exercise price	$ 12.45
Options vested in period \| shares	31,420
Number of vesting installments	8
Number of options to vest each installment \| shares	7,586
Expiration date	Apr. 09, 2024
Weighted average grant-date fair value	$ 781,391
Risk-free interest rate	1.65%
Expected volatility	82.06%
Expected term	5 years 2 months 16 days
Expected dividend yield	0.00%
Four Board of Directors members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted \| shares	52,376
Options granted, exercise price	$ 12.45
Number of vesting installments	2
Expiration date	Apr. 09, 2024
Weighted average grant-date fair value	$ 217,711
Risk-free interest rate	1.65%
Expected volatility	82.06%
Expected term	5 years 3 months
Expected dividend yield	0.00%
Subsidiary employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted \| shares	2,556
Options granted, exercise price	$ 12.45
Number of vesting installments	4
Expiration date	Apr. 09, 2024
Weighted average grant-date fair value	$ 21,220
Risk-free interest rate	1.65%
Expected volatility	82.06%
Expected term	5 years 2 months 23 days
Expected dividend yield	0.00%